Integrated analysis on mRNA microarray and microRNA microarray to screen immune-related biomarkers and pathways in myelodysplastic syndrome

References

• Ogawa S. Genetics of MDS. Blood. 2019;133:1049–1059.
   PubMed Web of Science ®Google Scholar
• Ganan-Gomez I, Wei Y, Starczynowski DT, et al. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia. 2015;29(7):1458–1469.
   PubMed Web of Science ®Google Scholar
• Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018;132(15):1553–1560.
   PubMed Web of Science ®Google Scholar
• Wang C, Yang Y, Gao S, et al. Immune dysregulation in myelodysplastic syndrome: clinical features, pathogenesis and therapeutic strategies. Crit Rev Oncol Hematol. 2018;122:123–132.
   PubMed Web of Science ®Google Scholar
• Giannouli S, Voulgarelis M, Zintzaras E, et al. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford). 2004;43(5):626–632.
   PubMed Web of Science ®Google Scholar
• Taki M, Fukutake K, Matsushita T, et al. Correction to: inhibitor development, safety, and efficacy of Advate(R) in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan. Int J Hematol. 2019;109(2):241.
   PubMed Web of Science ®Google Scholar
• Ramadan SM, Fouad TM, Summa V, et al. Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica. 2012;97(6):805–817.
   PubMed Web of Science ®Google Scholar
• Kristinsson S Y, Bjorkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29(21):2897–2903.
   PubMed Web of Science ®Google Scholar
• Al Ustwani O, Ford LA, Sait SJ, et al. Myelodysplastic syndromes and autoimmune diseases–case series and review of literature. Leuk Res. 2013;37(8):894–899.
   PubMed Web of Science ®Google Scholar
• Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822–828.
   PubMed Web of Science ®Google Scholar
• Datar GK, Goodel MA. Where there's smoke, there's fire: inflammation drives MDS. Trends Immunol. 2020;41(7):558–560.
   PubMed Web of Science ®Google Scholar
• Kuang X, Chi J, Wang L. Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes. Hematology. 2016;21(10):593–602.
   PubMed Web of Science ®Google Scholar
• Contreras J, Rao DS. MicroRNAs in inflammation and immune responses. Leukemia. 2012;26(3):404–413.
   PubMed Web of Science ®Google Scholar
• Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010;16(1):49–58.
   PubMed Web of Science ®Google Scholar
• Lee JH, List A, Sallman DA. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. Eur J Haematol. 2019;102(3):203–209.
   PubMed Web of Science ®Google Scholar
• Ganan-Gomez I, Wei Y, Yang H, et al. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-kappaB activation and enhances erythroid differentiation arrest. PLoS One. 2014;9(4):e93404.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Dunn P, Thomas CG, et al. Immport, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018;5:180015.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613.
   PubMed Web of Science ®Google Scholar
• Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43(Database issue):D146–D152.
   PubMedGoogle Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
   PubMed Web of Science ®Google Scholar
• Tang Y, Li M, Wang J, et al. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems. 2015;127:67–72.
   PubMed Web of Science ®Google Scholar
• Xie C, Mao X, Huang J, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 2011;39(Web Server issue):W316–W322.
   PubMedGoogle Scholar
• Kuninaka N, Kurata M, Yamamoto K, et al. Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia. Exp Mol Pathol. 2010;88(2):293–298.
   PubMed Web of Science ®Google Scholar
• Maratheftis CI, Andreakos E, Moutsopoulos HM, et al. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res. 2007;13(4):1154–1160.
   PubMed Web of Science ®Google Scholar
• Wei Y, Dimicoli S, Bueso-Ramos C, et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013;27(9):1832–1840.
   PubMed Web of Science ®Google Scholar
• Kornblau SM, McCue D, Singh N, et al. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 2010;116(20):4251–4261.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Finke C, Lasho TL, et al. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia. 2012;26(4):693–699.
   PubMed Web of Science ®Google Scholar
• Feng X, Scheinberg P, Wu CO, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica. 2011;96(4):602–606.
   PubMed Web of Science ®Google Scholar
• Glenthoj A, Orskov AD, Hansen JW, et al. Immune mechanisms in myelodysplastic syndrome. Int J Mol Sci. 2016;17(6):944.
   PubMed Web of Science ®Google Scholar
• Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133(10):1039–1048.
   PubMed Web of Science ®Google Scholar
• Zhao LP, Boy M, Azoulay C, et al. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 2021;Advance online publication.
   Web of Science ®Google Scholar
• Nézondet A-LC, Poubelle EP, et al. The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases. J Leukoc Biol. 2020;108(2):647–657.
   PubMed Web of Science ®Google Scholar
• Endele M, Etzrodt M, Schroeder T. Instruction of hematopoietic lineage choice by cytokine signaling. Exp Cell Res. 2014;329(2):207–213.
   PubMed Web of Science ®Google Scholar
• Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene. 2007;26(47):6738–6749.
   PubMed Web of Science ®Google Scholar
• Pyatt DW, Stillman WS, Yang Y, et al. An essential role for NF-κB in human CD34+ bone marrow cell survival. Blood. 1999;93(10):3302–3308.
   PubMed Web of Science ®Google Scholar
• Ji-Qing C, Szodoray P, Zeher M. Toll-like receptor pathways in autoimmune diseases. Clin Rev Allergy Immunol. 2016;50:1–17.
   PubMed Web of Science ®Google Scholar
• Paracatu LC, Schuettpelz LG. Contribution of aberrant Toll like receptor signaling to the pathogenesis of myelodysplastic syndromes. Front Immunol. 2020;11:1236.
   PubMed Web of Science ®Google Scholar
• Kulms D, Schwarz T. NF-κb and cytokines. Interleukins. 2006;74:283–300.
   Google Scholar
• de Matos AG, Ribeiro Junior HL, de Paula Borges D, et al. Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome. Med Oncol. 2017;34(10):168.
   PubMed Web of Science ®Google Scholar
• Schinke C, Giricz O, Li W, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 2015;125(20):3144–3152.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133(8):790–794.
   PubMed Web of Science ®Google Scholar
• Markham A. Luspatercept: first approval. Drugs. 2020;80(1):85–90.
   PubMed Web of Science ®Google Scholar
• Salvi V, Gianello V, Tiberio L, et al. Cytokine targeting by miRNAs in autoimmune diseases. Front Immunol. 2019;10:15.
   PubMed Web of Science ®Google Scholar